论文部分内容阅读
左旋咪唑(Levamisolum简称LMS)是一种人工合成的广谱低毒驱虫药,为四咪唑(驱虫净)的左旋体、具有驱除肠道及其他部位寄生虫的作用。1971年Renoux发现其具有激发动物免疫机能,增强抗感染作用后,LMS又作为一种免疫增强剂,在复发性上呼吸道感染、复发性口腔炎,类风湿性关节炎及恶性肿瘤等疾病中试用。近年来LMS的临床应用范围日益广泛,其临床实用价值以及不良反应已越来越被人们所认识。LMS是一种非特异性免疫增强剂,具有:(1)能使受抑制的巨噬细胞和T淋巴细胞功能恢复正常。这是由于活化了磷酸二酯酶,使环磷酸腺苷(cAMP)减少,环磷酸鸟苷(cGMP)增加所致。(2)能使血清免疫球蛋白——IgG、IgA增加。(3)增加血清总补体(CH_(60))水平等免疫调节作用。
Levamisolum (LMS) is a synthetic broad-spectrum, low-toxicity deworming drug, which is the levamisole of tetraimidazole (NET) and has the function of repelling intestinal parasites and other parts. After Renoux discovered in 1971 that it could stimulate the immune function of animals and enhance the anti-infective effect, LMS also served as an immunostimulant in trials of recurrent upper respiratory tract infections, recurrent stomatitis, rheumatoid arthritis and malignant tumors . In recent years, LMS clinical application of a growing range of its clinical value and adverse reactions have been more and more people know. LMS is a nonspecific immunopotentiator with: (1) normalized suppressive function of macrophages and T lymphocytes. This is due to activation of phosphodiesterase, reduction of cAMP, and increased cGMP. (2) can make serum immunoglobulin - IgG, IgA increased. (3) increase the serum total complement (CH_ (60)) levels and other immunomodulatory effects.